BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dahele M, Palma D, Lagerwaard F, Slotman B, Senan S. Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer. Journal of Thoracic Oncology 2011;6:1221-8. [DOI: 10.1097/jto.0b013e318219aac5] [Cited by in Crossref: 99] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Al-umairi R, Tarique U, Moineddin R, Jimenez-juan L, Kha LC, Cheung P, Oikonomou A. CT patterns and serial CT Changes in lung Cancer patients post stereotactic body radiotherapy (SBRT). Cancer Imaging 2022;22. [DOI: 10.1186/s40644-022-00491-1] [Reference Citation Analysis]
2 Bansal S, Bechara RI, Patel JD, Mehta HJ, Ferguson JS, Witt BL, Murgu SD, Yasufuku K, Casal RF. Safety and Feasibility of Photodynamic Therapy for Ablation of Peripheral Lung Tumors. J Bronchology Interv Pulmonol 2022. [PMID: 35968968 DOI: 10.1097/LBR.0000000000000889] [Reference Citation Analysis]
3 Yang H, Wang L, Shao G, Dong B, Wang F, Wei Y, Li P, Chen H, Chen W, Zheng Y, He Y, Zhao Y, Du X, Sun X, Wang Z, Wang Y, Zhou X, Lai X, Feng W, Shen L, Qiu G, Ji Y, Chen J, Jiang Y, Liu J, Zeng J, Wang C, Zhao Q, Yang X, Hu X, Ma H, Chen Q, Chen M, Jiang H, Xu Y. A combined predictive model based on radiomics features and clinical factors for disease progression in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. Front Oncol 2022;12:967360. [DOI: 10.3389/fonc.2022.967360] [Reference Citation Analysis]
4 Dejanovic D, Specht L, Czyzewska D, Kiil Berthelsen A, Loft A. Response Evaluation Following Radiation Therapy With 18F-FDG PET/CT: Common Variants of Radiation-Induced Changes and Potential Pitfalls. Semin Nucl Med 2022:S0001-2998(22)00055-1. [PMID: 35835618 DOI: 10.1053/j.semnuclmed.2022.06.001] [Reference Citation Analysis]
5 Matsumoto Y. A pictorial essay on radiological changes after stereotactic body radiation therapy for lung tumors. Jpn J Radiol. [DOI: 10.1007/s11604-022-01252-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sodji QH, Harris JP, Quon A, Modlin LA, Lau B, Jiang A, Trakul N, Maxim PG, Diehn M, Loo BW, Hiniker SM. Detection of Recurrence after Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.01.006] [Reference Citation Analysis]
7 Lee K, Le T, Hau E, Hanna GG, Gee H, Vinod S, Dammak S, Palma D, Ong A, Yeghiaian-Alvandi R, Buck J, Lim R. A systematic review into the radiological features predicting local recurrence after stereotactic ablative body radiotherapy (SABR) in patients with non-small cell lung cancer (NSCLC): Local recurrence features of NSCLC post-SABR. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)03235-1. [PMID: 34879247 DOI: 10.1016/j.ijrobp.2021.11.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kashihara T. SABR for operable stage I non-small-cell lung cancer: comparison to surgery. Lancet Oncol 2021;22:e534. [PMID: 34856144 DOI: 10.1016/S1470-2045(21)00594-5] [Reference Citation Analysis]
9 Walls GM, Osman SOS, Brown KH, Butterworth KT, Hanna GG, Hounsell AR, McGarry CK, Leijenaar RTH, Lambin P, Cole AJ, Jain S. Radiomics for Predicting Lung Cancer Outcomes Following Radiotherapy: A Systematic Review. Clin Oncol (R Coll Radiol) 2021:S0936-6555(21)00372-1. [PMID: 34763965 DOI: 10.1016/j.clon.2021.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
10 Yang Y, Li G, Li S, Wang Y, Zhao Y, Dong B, Wang J, Zhu R, Chen M. CT Appearance Pattern After Stereotactic Body Radiation Therapy Predicts Outcomes in Early-Stage Non-Small-Cell Lung Cancer. Front Oncol 2021;11:746785. [PMID: 34707992 DOI: 10.3389/fonc.2021.746785] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Itonaga T, Sugahara S, Mikami R, Saito T, Yamada T, Kurooka M, Shiraishi S, Okubo M, Saito K. Evaluation of the relationship between the range of radiation-induced lung injury on CT images after IMRT for stage I lung cancer and dosimetric parameters. Ann Med 2021;53:267-73. [PMID: 33430616 DOI: 10.1080/07853890.2020.1869297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bousabarah K, Blanck O, Temming S, Wilhelm ML, Hoevels M, Baus WW, Ruess D, Visser-Vandewalle V, Ruge MI, Treuer H, Kocher M. Radiomics for prediction of radiation-induced lung injury and oncologic outcome after robotic stereotactic body radiotherapy of lung cancer: results from two independent institutions. Radiat Oncol 2021;16:74. [PMID: 33863358 DOI: 10.1186/s13014-021-01805-6] [Reference Citation Analysis]
13 Liu Y, Zhu Y, Wu R, Hu M, Zhang L, Lin Q, Weng D, Sun X, Liu Y, Xu Y. Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease. Transl Lung Cancer Res 2020;9:2328-36. [PMID: 33489796 DOI: 10.21037/tlcr-20-1050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Koizumi T, Aoki T, Saito M, Yamato Y, Furuyashiki G, Kitahara A, Hashimoto T, Watanabe T, Tsuchida M. Salvage surgery to treat tumor regrowth after stereotactic body radiotherapy in primary non-small cell lung cancer. J Thorac Dis 2020;12:5289-98. [PMID: 33209363 DOI: 10.21037/jtd-20-2253] [Reference Citation Analysis]
15 Käsmann L, Dietrich A, Staab-Weijnitz CA, Manapov F, Behr J, Rimner A, Jeremic B, Senan S, De Ruysscher D, Lauber K, Belka C. Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiat Oncol 2020;15:214. [PMID: 32912295 DOI: 10.1186/s13014-020-01654-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
16 Frerker B, Hildebrandt G. Distinguishing Radiation Pneumonitis from Local Tumour Recurrence Following SBRT for Lung Cancer

]]>. RMI 2020;Volume 13:1-23. [DOI: 10.2147/rmi.s176901] [Reference Citation Analysis]
17 Kim TH, Woo S, Halpenny DF, Kim YJ, Yoon SH, Suh CH. Can high-risk CT features suggest local recurrence after stereotactic body radiation therapy for lung cancer? A systematic review and meta-analysis. Eur J Radiol 2020;127:108978. [PMID: 32298960 DOI: 10.1016/j.ejrad.2020.108978] [Reference Citation Analysis]
18 Gouveia AG, Zalay OC, Chua KL, Moraes FY. Response evaluation after stereotactic ablative radiotherapy for localised non-small-cell lung cancer: an equipoise of available resource and accuracy. Br J Radiol 2020;93:20190647. [PMID: 31778312 DOI: 10.1259/bjr.20190647] [Reference Citation Analysis]
19 Halpenny D, O'Dwyer E, Camacho Vasquez J, Shaverdian N, Girshman J, Ginsberg MS. Imaging of Novel Oncologic Treatments in Lung Cancer Part 2: Local Ablative Therapies. J Thorac Imaging 2020;35:37-48. [PMID: 31592831 DOI: 10.1097/RTI.0000000000000452] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Roy SF, Louie AV, Liberman M, Wong P, Bahig H. Pathologic response after modern radiotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2019;8:S124-34. [PMID: 31673516 DOI: 10.21037/tlcr.2019.09.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
21 Halpenny D, Raj M, Rimner A, Zheng J, Capanu M, Ginsberg MS. Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy. Eur Radiol 2019;29:3696-704. [PMID: 30689034 DOI: 10.1007/s00330-018-5937-6] [Reference Citation Analysis]
22 McDonald AM, Colvin T, Boggs DH, Spencer SA, Popple RA, Clayton R, Minnich D, Dobelbower MC. Longitudinal assessment of anchored transponder migration following lung stereotactic body radiation therapy. J Appl Clin Med Phys 2019;20:17-22. [PMID: 30387242 DOI: 10.1002/acm2.12454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Nakamura N, Hojo H, Inoue K, Hotta K, Zenda S, Baba H, Onozawa M, Motegi A, Nakamura M, Kibe Y, Akimoto T. Late radiological changes after passive scattering proton beam therapy for Stage I lung cancer. J Radiat Res 2018;59:456-61. [PMID: 29790995 DOI: 10.1093/jrr/rry028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Yamamoto T, Kadoya N, Morishita Y, Sato Y, Matsushita H, Umezawa R, Ishikawa Y, Takahashi N, Katagiri Y, Takeda K, Jingu K. Assessment and agreement of the CT appearance pattern and its severity grading of radiation-induced lung injury after stereotactic body radiotherapy for lung cancer. PLoS One 2018;13:e0204734. [PMID: 30286105 DOI: 10.1371/journal.pone.0204734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Frick MA, Kao GD, Aguarin L, Chinniah C, Swisher-McClure S, Berman AT, Levin WP, Cengel KA, DeCesaris C, Hahn SM, Dorsey JF, Simone CB 2nd. Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study. Int J Radiat Oncol Biol Phys 2018;102:536-42. [PMID: 30244877 DOI: 10.1016/j.ijrobp.2018.06.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
26 Kalman NS, Hugo GD, Kahn JM, Zhao SS, Jan N, Mahon RN, Weiss E. Interobserver reliability in describing radiographic lung changes after stereotactic body radiation therapy. Adv Radiat Oncol 2018;3:655-61. [PMID: 30370367 DOI: 10.1016/j.adro.2018.05.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Dyer BA, Daly ME. Surveillance imaging following definitive radiotherapy for non-small cell lung cancer: What is the clinical impact? Semin Oncol 2017;44:303-9. [PMID: 29580432 DOI: 10.1053/j.seminoncol.2018.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Tyran M, Charrier N, Darreon J, Madroszyk A, Tallet A, Salem N. Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control. In Vivo 2018;32:121-4. [PMID: 29275308 DOI: 10.21873/invivo.11213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Li Q, Kim J, Balagurunathan Y, Qi J, Liu Y, Latifi K, Moros EG, Schabath MB, Ye Z, Gillies RJ, Dilling TJ. CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy. Radiat Oncol 2017;12:158. [PMID: 28946909 DOI: 10.1186/s13014-017-0892-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
30 Hörner-Rieber J, Dern J, Bernhardt D, König L, Adeberg S, Verma V, Paul A, Kappes J, Hoffmann H, Debus J, Heussel CP, Rieken S. Parenchymal and Functional Lung Changes after Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer-Experiences from a Single Institution. Front Oncol 2017;7:215. [PMID: 28975083 DOI: 10.3389/fonc.2017.00215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Nguyen TK, Palma DA. Pros: After stereotactic ablative radiotherapy for a peripheral early-stage non-small cell lung cancer, radiological suspicion of a local recurrence can be sufficient indication to proceed to salvage therapy. Transl Lung Cancer Res 2016;5:647-50. [PMID: 28151535 DOI: 10.21037/tlcr.2016.12.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Baker S, Dahele M, Lagerwaard FJ, Senan S. A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol 2016;11:115. [PMID: 27600665 DOI: 10.1186/s13014-016-0693-8] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 12.5] [Reference Citation Analysis]
33 Boda-Heggemann J, Attenberger U, Budjan J, Jahnke A, Jahnke L, Vogel L, Simeonova-Chergou AO, Herskind C, Wenz F, Lohr F. MRI morphologic alterations after liver SBRT : Direct dose correlation with intermodal matching. Strahlenther Onkol 2016;192:641-8. [PMID: 27393400 DOI: 10.1007/s00066-016-1013-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
34 Mattonen SA, Ward AD, Palma DA. Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply? Br J Radiol 2016;89:20160113. [PMID: 27245137 DOI: 10.1259/bjr.20160113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
35 Mazzola R, Fiorentino A, Ricchetti F, Giaj Levra N, Fersino S, Di Paola G, Lo Casto A, Ruggieri R, Alongi F. Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response. Br J Radiol 2016;89:20160146. [PMID: 27245138 DOI: 10.1259/bjr.20160146] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
36 Sawada S, Suehisa H, Ueno T, Sugimoto R, Yamashita M. Monitoring and management of lung cancer patients following curative-intent treatment: clinical utility of 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography/computed tomography. Lung Cancer (Auckl) 2016;7:45-51. [PMID: 28210160 DOI: 10.2147/LCTT.S83644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Binkley MS, Shrager JB, Chaudhuri A, Popat R, Maxim PG, Shultz DB, Diehn M, Loo BW Jr. Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors. Radiat Oncol 2016;11:40. [PMID: 26975700 DOI: 10.1186/s13014-016-0616-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
38 Amini B, Beaman CB, Madewell JE, Allen PK, Rhines LD, Tatsui CE, Tannir NM, Li J, Brown PD, Ghia AJ. Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials. AJNR Am J Neuroradiol 2016;37:387-92. [PMID: 26494690 DOI: 10.3174/ajnr.A4528] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
39 Cascales A, Martinetti F, Belemsagha D, Le Pechoux C. Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy? Transl Lung Cancer Res 2014;3:195-204. [PMID: 25806301 DOI: 10.3978/j.issn.2218-6751.2014.08.03] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
40 Hayashi S, Tanaka H, Hoshi H. Imaging characteristics of local recurrences after stereotactic body radiation therapy for stage I non-small cell lung cancer: Evaluation of mass-like fibrosis. Thorac Cancer 2015;6:186-93. [PMID: 26273357 DOI: 10.1111/1759-7714.12162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
41 Arcangeli S, Agolli L, Portalone L, Migliorino MR, Lopergolo MG, Monaco A, Dognini J, Pressello MC, Bracci S, Donato V. Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC. Br J Radiol 2015;88:20140728. [PMID: 25645106 DOI: 10.1259/bjr.20140728] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
42 Halpenny D, Ridge CA, Hayes S, Zheng J, Moskowitz CS, Rimner A, Ginsberg MS. Computed tomographic features predictive of local recurrence in patients with early stage lung cancer treated with stereotactic body radiation therapy. Clin Imaging 2015;39:254-8. [PMID: 25571791 DOI: 10.1016/j.clinimag.2014.12.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
43 Chehade S, Palma DA. Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions. Rep Pract Oncol Radiother 2015;20:403-10. [PMID: 26696779 DOI: 10.1016/j.rpor.2014.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
44 Sun Y, Lu Y, Cheng S, Guo W, Ye K, Zhao H, Zheng X, Li D, Wang S, Yang C, Ge H. Interfractional variations of tumor centroid position and tumor regression during stereotactic body radiotherapy for lung tumor. Biomed Res Int 2014;2014:372738. [PMID: 25548770 DOI: 10.1155/2014/372738] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
45 Dorsey JF, Kao GD, MacArthur KM, Ju M, Steinmetz D, Wileyto EP, Simone CB 2nd, Hahn SM. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results. Cancer 2015;121:139-49. [PMID: 25241991 DOI: 10.1002/cncr.28975] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 8.4] [Reference Citation Analysis]
46 Amini A, Yeh N, Gaspar LE, Kavanagh B, Karam SD. Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiat Oncol 2014;9:210. [PMID: 25239200 DOI: 10.1186/1748-717X-9-210] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
47 Mattonen SA, Huang K, Ward AD, Senan S, Palma DA. New techniques for assessing response after hypofractionated radiotherapy for lung cancer. J Thorac Dis 2014;6:375-86. [PMID: 24688782 DOI: 10.3978/j.issn.2072-1439.2013.11.09] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
48 Jain P, Baker A, Distefano G, Scott AJ, Webster GJ, Hatton MQ. Stereotactic ablative radiotherapy in the UK: current status and developments. Br J Radiol 2013;86:20130331. [PMID: 23873906 DOI: 10.1259/bjr.20130331] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
49 Mattonen SA, Palma DA, Haasbeek CJ, Senan S, Ward AD. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes. Acta Oncol 2013;52:910-8. [PMID: 23106174 DOI: 10.3109/0284186X.2012.731525] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
50 Singhvi M, Lee P. Illustrative cases of false positive biopsies after stereotactic body radiation therapy for lung cancer based on abnormal FDG-PET-CT imaging. BMJ Case Rep 2013;2013:bcr2012007967. [PMID: 23345491 DOI: 10.1136/bcr-2012-007967] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
51 Ohri N, Werner-Wasik M, Grills IS, Belderbos J, Hope A, Yan D, Kestin LL, Guckenberger M, Sonke JJ, Bissonnette JP, Xiao Y. Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group. Int J Radiat Oncol Biol Phys 2012;84:e379-84. [PMID: 22999272 DOI: 10.1016/j.ijrobp.2012.04.040] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
52 Senan S, Palma DA, Lagerwaard FJ. Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies. J Thorac Dis 2011;3:189-96. [PMID: 22263087 DOI: 10.3978/j.issn.2072-1439.2011.05.03] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
53 Dahele M, Senan S. The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. Cancer Res Treat 2011;43:75-82. [PMID: 21811422 DOI: 10.4143/crt.2011.43.2.75] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]